Related Experiment Video
Updated: May 18, 2026

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease
Published on: April 28, 2019
Severe hemorrhagic fever in strain 13/N guinea pigs infected with Lujo virus
Brian H Bird1, Kimberly A Dodd, Bobbie R Erickson
1Viral Special Pathogens Branch, Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America. bbird1@cdc.gov
Abstract:
Lujo virus (LUJV) is a novel member of the Arenaviridae family that was first identified in 2008 after an outbreak of severe hemorrhagic fever (HF). In what was a small but rapidly progressing outbreak, this previously unknown virus was transmitted from the critically ill index patient to 4 attending healthcare workers. Four persons died during this outbreak, for a total case fatality of 80% (4/5). The suspected rodent source of the initial exposure to LUJV remains a mystery. Because of the ease of transmission, high case fatality, and novel nature of LUJV, we sought to establish an animal model of LUJV HF. Initial attempts in mice failed, but infection of inbred strain 13/N guinea pigs resulted in lethal disease. A total of 41 adult strain 13/N guinea pigs were infected with either wild-type LUJV or a full-length recombinant LUJV. Results demonstrated that strain 13/N guinea pigs provide an excellent model of severe and lethal LUJV HF that closely resembles what is known of the human disease. All infected animals experienced consistent weight loss (3-5% per day) and clinical illness characterized by ocular discharge, ruffled fur, hunched posture, and lethargy. Uniform lethality occurred by 11-16 days post-infection. All animals developed disseminated LUJV infection in various organs (liver, spleen, lung, and kidney), and leukopenia, lymphopenia, thrombocytopenia, coagulopathy, and elevated transaminase levels. Serial euthanasia studies revealed a temporal pattern of virus dissemination and increasing severity of disease, primarily targeting the liver, spleen, lungs, and lower gastrointestinal tract. Establishing an animal LUJV model is an important first step towards understanding the high pathogenicity of LUJV and developing vaccines and antiviral therapeutic drugs for this highly transmissible and lethal emerging pathogen.
Insights
Lujo virus (LUJV) causes severe hemorrhagic fever (HF) with high fatality. Strain 13/N guinea pigs effectively model LUJV HF, aiding research into this emerging pathogen.
Area of Science:
- Virology
- Infectious Diseases
- Pathogen Research
Background:
- Lujo virus (LUJV), a novel Arenaviridae family member, emerged in 2008 causing severe hemorrhagic fever (HF).
- The initial outbreak demonstrated high transmissibility among healthcare workers and an 80% case fatality rate.
- The suspected zoonotic source of LUJV remains unidentified.
Purpose of the Study:
- To establish a reliable animal model for studying Lujo virus hemorrhagic fever (LUJV HF).
- To investigate the pathogenesis of LUJV infection in a susceptible animal model.
- To provide a foundation for developing LUJV countermeasures.
Main Methods:
- Infection of adult strain 13/N guinea pigs with wild-type or recombinant Lujo virus (LUJV).
- Monitoring of clinical signs, weight loss, and survival rates post-infection.
- Assessment of viral dissemination, organ pathology, and hematological/biochemical changes through serial euthanasia studies.
Main Results:
- Strain 13/N guinea pigs developed severe, lethal LUJV HF closely mimicking human disease.
- Infected animals exhibited consistent weight loss, clinical illness, and uniform lethality within 11-16 days.
- Disseminated LUJV infection was observed in multiple organs, accompanied by leukopenia, thrombocytopenia, coagulopathy, and elevated transaminases.
Conclusions:
- Strain 13/N guinea pigs serve as an excellent animal model for Lujo virus hemorrhagic fever.
- This model facilitates the study of LUJV's high pathogenicity and transmission dynamics.
- The established model is crucial for advancing research on LUJV vaccines and antiviral therapies.

